Skip to content

An exploratory study on the feasibility of endovascular therapy for arterial erectile dysfunction

An exploratory study on the feasibility of endovascular therapy for arterial erectile dysfunction

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051461
Enrollment
Unknown
Registered
2021-09-24
Start date
2021-11-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial erectile dysfunction

Interventions

Sponsors

The First Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
22 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. Male subjects aged 22 to 76 years with a stable partner (over 6 months); 2. ED subjects with unsatisfactory efficacy after treatment with PDE5i drugs; 3. Angiographic criteria: invasive DSA shows that ED-related arteries have >=50% stenosis, and the vessel diameter is >=2mm; 4. Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. There is intolerance to antithrombotic drugs such as aspirin, clopidogrel, and heparin; 2. There are other uncorrected causes of ED, such as: hypogonadism, prostatectomy, pelvic injury, hormonal abnormalities, mental illness, drug-related factors, etc.; 3. Have severe cardiovascular and cerebrovascular diseases, have suffered myocardial infarction, angina pectoris, severe arrhythmia within 3 months before screening, or are receiving nitrate drug treatment; 4. There is >=50% obstructive stenosis in ED-related arteries with a diameter of less than 2 mm at the distal end of the target lesion; 5. Expected survival time < 12 months; 6. Those who are expected to have a birth plan within 6 months; 7. Other circumstances that the investigator considers inappropriate for inclusion.

Design outcomes

Primary

MeasureTime frame
Clinical success rate at 6 months after surgery;

Secondary

MeasureTime frame
Clinical success rate at 1 and 12 months after surgery;Target lesion restenosis rate confirmed by pelvic computed tomography at 8 months after surgery;

Countries

China

Contacts

Public ContactDeng Chunhua

The First Affiliated Hospital, Sun Yat-Sen University

13501519349@163.com+86 13501519349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026